- Home
- CANF vs ADXN Comparison
CANF vs ADXN Comparison
Compare CANF & ADXN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CANF
- ADXN
- Stock Information
- Founded
- CANF 1994
- ADXN 2002
- Country
- CANF Israel
- ADXN Switzerland
- Employees
- CANF N/A
- ADXN N/A
- Industry
- CANF Biotechnology: Pharmaceutical Preparations
- ADXN Biotechnology: Pharmaceutical Preparations
- Sector
- CANF Health Care
- ADXN Health Care
- Exchange
- CANF Nasdaq
- ADXN Nasdaq
- Market Cap
- CANF 9.4M
- ADXN 8.0M
- IPO Year
- CANF N/A
- ADXN N/A
- Fundamental
- Price
- CANF $1.54
- ADXN $7.70
- Analyst Decision
- CANF Strong Buy
- ADXN Strong Buy
- Analyst Count
- CANF 2
- ADXN 1
- Target Price
- CANF $14.00
- ADXN $30.00
- AVG Volume (30 Days)
- CANF 117.2K
- ADXN 27.2K
- Earning Date
- CANF 02-03-2025
- ADXN 11-22-2024
- Dividend Yield
- CANF N/A
- ADXN N/A
- EPS Growth
- CANF N/A
- ADXN N/A
- EPS
- CANF N/A
- ADXN 0.06
- Revenue
- CANF $667,000.00
- ADXN $701,260.00
- Revenue This Year
- CANF $409.56
- ADXN N/A
- Revenue Next Year
- CANF N/A
- ADXN N/A
- P/E Ratio
- CANF N/A
- ADXN $1.05
- Revenue Growth
- CANF N/A
- ADXN N/A
- 52 Week Low
- CANF $1.29
- ADXN $7.00
- 52 Week High
- CANF $4.69
- ADXN $27.90
- Technical
- Relative Strength Index (RSI)
- CANF 42.93
- ADXN 47.44
- Support Level
- CANF $1.55
- ADXN $7.35
- Resistance Level
- CANF $1.64
- ADXN $8.40
- Average True Range (ATR)
- CANF 0.10
- ADXN 0.74
- MACD
- CANF 0.01
- ADXN 0.03
- Stochastic Oscillator
- CANF 11.76
- ADXN 36.27
About CANF Can-Fite Biopharma Ltd Sponsored ADR (Israel)
Can Fite Biofarma Ltd is an clinical-stage biopharmaceutical company. The company develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver and inflammatory diseases. The company's platform technology utilizes the Gi protein associated A3 adenosine receptor, or A3AR, as a therapeutic target. The company's drug candidate, Piclidenoson, is currently in a Phase III trial for psoriasis. Can-Fite's liver drug, Namodenoson, is headed into a Phase III trial for hepatocellular carcinoma (HCC), the common form of liver cancer, and a Phase IIb trial for the treatment of non-alcoholic steatohepatitis (NASH).
About ADXN Addex Therapeutics Ltd
Addex Therapeutics Ltd is a clinical stage biopharmaceutical company. The company is focused on the development and commercialization of an emerging class of novel orally available small-molecule drugs known as allosteric modulators. The company's geographical area of operations includes Switzerland and Europe. The Company operates in one segment which is the discovery, development and commercialization of small-molecule pharmaceutical products.